期刊文献+

复制缺陷型人TPO重组腺病毒的构建与鉴定 被引量:3

Construction and identification of replication deficient human thrombopoietin recombinant adenoviruses
下载PDF
导出
摘要 目的:构建并鉴定携带人TPO基因的复制缺陷型重组腺病毒。方法:将含全部编码序列的人TPOcDNA克隆于腺病毒载体穿梭质粒pCA3的CMV启动子下游,然后与含有腺病毒基因组的质粒pB-HG10共转染293细胞,经同源重组产生人TPO重组腺病毒(AdCMVTPO);体外转染A549细胞并检测其表达活性。结果:扩增后获得的病毒滴度达4.5×109pfu/ml,经体外转染A549细胞检测到TPO的表达。结论:所构建的重组腺病毒能有效介导人TPO基因的转移,可望用于造血功能重建的基因治疗研究。 Objective: To construct and identify the replication-deficient human thrombopoietin (TPO) recombinant adenoviruses (AdCMVTPO). Methods: The fulllength human TPO encoding TPO cDNA was cloned at the down stream of human CMV promoter of adenoviral shuttle plasmid pCA3. Then the resultant pCA3TPO was cotransfected into 293 cells with the plasmid pBHG10 carrying the adenoviral genome. The AdCMVTPO was successfully generated with homologous recombination. A549 cells were infected with AdCMVTPO and the expression of human TPO was evaluated in vivo. Results: The titer of AdCMVTPO reached 4.5109 pfu/ml after amplification in 293 cells. A549 cells expressed high level of human TPO after infection. Conclusion: The constructed recombinant adenovirus can mediate the human TPO gene transfer efficiently and can be used in the gene therapy of hemopoietic reconstruction.
出处 《第三军医大学学报》 CAS CSCD 北大核心 1999年第5期314-317,共4页 Journal of Third Military Medical University
基金 重庆市应用基础研究基金
关键词 血小板生成素 腺病毒载体 基因治疗 造血功能 thrombopoietin adenovirus gene transfer gene therapy
  • 相关文献

同被引文献15

  • 1Reichardt P, Tilgner J, Hohenberger P, et al. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study[J].J Clin Oncol,1998,16(4):1438.
  • 2Crawford J, George M. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy[J].Semin Oncol,1995,22(3 Suppl 7):18.
  • 3Yan XQ, Lacey D, Fletcher F, et al. Chronic exposure to retroviral vector encoded MGDF(mpl-ligand) induces lineage-specific growth and differentiaton of megakaryocytes in mice[J].Blood,1995,96:4025.
  • 4Konishi H, Ochiya T, Sakamoto H, et al. Effective prevention of thrombocytopenia using adenovirus-mediated transfer of HST-11FGF-4 gene: in vivo and in vitro studies[J]. Leukemia,1997,11(Suppl 3):530.
  • 5Mashhour B, Couton D, Perricaudet M. In vivo adenovirus-mediated gene transfer into ocular tissues[J].Gene Ther,1994,1(2):122.
  • 6Eaton DL, de Sauvage FJ. Thrombopoietin: the primary regulator of megakaryocytopoiesis and thrombopoiesis[J].Exp Hematol,1997,25(1):1.
  • 7Yamada M, Komatsu N, Kirito K, et al. Thrombopoietin supports in vitro erythroid differentiation via its specific receptor c-Mpl in a human leukemia cell line[J].Cell Growth Differ,1998,9(6):487.
  • 8Tanimukai S, Kimura T, Sakabe H, et al. Recombinant human c-Mpl ligand (thrombopoietin) not only acts on megakaryocyte progenitors, but also on erythroid and multipotential progenitors in vitro[J].Exp Hematol,1997,25(10):1025.
  • 9Wagemaker G, Neelis KJ, Hartong SC, et al. The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation[J].Stem Cells,1998,16(6):375..
  • 10Drachman JG. Role of thrombopoietin in hematopoietic stem cell and progenitor regulation. [J]. Curr Opin Hematol,2000,7(3):183.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部